In reply: Badami suggests that international normalised ratio (INR)-based prothrombin complex concentrate (PCC) dosing for warfarin reversal may not be clinically useful and is cumbersome to use. We agree that the INR variably reflects factor II, VII, IX and X activity in patients on warfarin therapy. However, the INR is a rapid, valid and readily available test, and an INR-based PCC dosing regimen provides guidance on how to manage patients on warfarin therapy who have major bleeds or need urgent surgery. We acknowledge that further validation of the INR-based dosing regimen is needed, but only a randomised trial comparing INR-based dosing with fixed-dose PCC treatment will give clarity.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Kruger PC, Le Viellez AS, Herrmann RP. Prothrombinex-VF use in warfarin reversal and other indications. Med J Aust 2012; 196: 462-465. <MJA full text>
- 2. Tran H, Collecutt M, Whitehead S, Salem HH. Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation. Intern Med J 2011; 41: 337-343.
- 3. Hanger HC, Geddes JA, Wilkinson TJ, et al. Warfarin-related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates. Intern Med J 2013; 43: 308-316.
No relevant disclosures.